Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20150275183Human Betacoronavirus lineage C and identification of N-terminal dipeptidyl peptidase as its virus receptor
US 01.10.2015
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No 14430010 Applicant Erasmus University Medical Center Rotterdam Inventor Bartholomeus Leonardus Haagmans

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

2.WO/2021/209275PARTICLES, DNA & RNA
WO 21.10.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/EP2021/058821 Applicant NOVOSCOPE IP LIMITED Inventor CLUBE, Jasper
The invention provides competitive particles, such as virus-like particles, RNAs and DNAs for the treatment or prevention of viral infections and methods of using such particles for treating or preventing or reducing the risk of viral infections (or symptoms thereof) in a subject, such as a human or animal subject. For example, the method herein is a method of reducing or reducing the establishment of a zoonotic population of a virus in an animal, such as a livestock or wild animal (eg, a bat, camelid or a Pholidota (eg, a pangolin)).
3.WO/2021/181276COMPOSITION COMPRISING LACTOFERRIN AND PROBIOTIC BACTERIAL STRAINS FOR ORAL USE WITH ANTIVIRAL ACTION
WO 16.09.2021
Int.Class A61K 38/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
Appl.No PCT/IB2021/051959 Applicant SOFAR S.P.A. Inventor BIFFI, Andrea
The present invention relates to a composition comprising lactoferrin and, optionally, probiotic bacterial strains and/or N-acetylcysteine and/or hyaluronic acid for oral use as an antiviral agent, preferably for use in the treatment of viral infections of the respiratory system from a SARS-coronavirus (e.g. COVID-19).
4.WO/2022/096708A COMPOSITION COMPRISING EXTRA-CELLULAR VESICLES FROM MESENCHYMAL STEM CELLS AND ALPHA-1 ANTITRYPSIN FOR THE TREATMENT OF VIRAL INFECTIONS
WO 12.05.2022
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/EP2021/080936 Applicant AATEC MEDICAL GMBH Inventor STANGL, Manfred
The invention relates to a pharmaceutical composition comprising extra-cellular vesicles isolated from mesenchymal stem cells (MSCs) and Alpha-1 antitrypsin (AAT) protein, for use as a medicament in the treatment and/or prevention of a viral infection in a human subject. The invention further relates to the composition for topical and/or local administration to a mucosal surface of the respiratory tract and/or in the oral cavity of the subject. In another aspect the invention relates to a delivery system and corresponding formulations for dispensing the pharmaceutical composition.
5.20230270792REDUCTION OF COVID-19 COAGULOPATHY AND OTHER INFLAMMATION-ASSOCIATED COAGULOPATHIES BY ADMINISTRATION OF FIBROBLASTS
US 31.08.2023
Int.Class A61K 35/33
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
33Fibroblasts
Appl.No 18040345 Applicant FIGENE, LLC Inventor Pete O'HEERON

Embodiments of the disclosure include methods and compositions for treatment or reduction in risk of coagulopathy of any kind, including associated with inflammation. In specific embodiments, the coagulopathy is associated with upregulated production of tissue factor in the individual. In specific embodiments, the coagulopathy is in an individual that has SARS-CoV-2 infection or is at risk for having SARS-CoV-2 infection. In specific embodiments, the methods and compositions include fibroblasts, and/or modified fibroblasts, and/or derivatives of fibroblasts, including those fibroblasts exposed to TNF-alpha or one or more other inflammatory agents before activation of the fibroblasts.

6.WO/2021/242798SURFACE DISPLAY OF PROTEINS ON RECOMBINANT BACTERIA AND USES THEREOF
WO 02.12.2021
Int.Class A61K 35/66
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
Appl.No PCT/US2021/034137 Applicant SYNLOGIC OPERATING COMPANY, INC. Inventor LI, Ning
Recombinant microorganisms, pharmaceutical compositions thereof, and methods of protein display on the cell surface of the microorganisms are disclosed.
7.WO/2025/012121TGF-ß INHIBITION AND ENGINEERED T-CELLS FOR THE TREATMENT OF COVID-19 SEQUELAE AND VIRUS-INDUCED HYPERINFLAMMATION
WO 16.01.2025
Int.Class A61K 38/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
Appl.No PCT/EP2024/069010 Applicant DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN Inventor MASHREGHI, Mir-Farzin
The invention relates in one aspect to a TGF-β inhibitor for use in the treatment of virus-induced hyperinflammation or (post-)COVID-19 infection symptoms or sequelae, wherein the patient is suffering from or experiencing elevated (above-normal) expression, excretion and/or blood levels of transforming growth factor-β (TGF-β) and/or interferon. The invention relates also to a TGF-β inhibitor for use in the treatment of COVID-19-induced hyperinflammation or (post-)COVID-19 symptoms or sequelae or Long-COVID-19. In another aspect the invention relates to a method for stimulating T cells and to a T-cell for the use in the treatment of virus reactivation and/or SARS- CoV-2-induced hyperinflammation.
8.WO/2021/226602PLACENTA-DERIVED ADHERENT (PDA) STEM CELL FOR THE TREATMENT OF ADULTS WITH SARS-COV-2 RELATED ACUTE RESPIRATORY FAILURE AND ARDS (COVID-19)
WO 11.11.2021
Int.Class A61K 35/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
50Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
Appl.No PCT/US2021/031649 Applicant CELULARITY INC. Inventor HARIRI, Robert J.
Provided herein are methods of using CD10+, CD34-, CD105+, CD200+ tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of SARS-CoV-2 related acute respiratory failure and ARDS (COVID-19).
9.WO/2023/288046COMPOSITIONS AND METHODS RELATING TO CELLS WITH ADHERED PARTICLES
WO 19.01.2023
Int.Class A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Appl.No PCT/US2022/037261 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor MITRAGOTRI, Samir
Provided herein are polymeric particles and compositions (i.e., "backpacks") that can adhere to cells and provide delivery of payload agents to those cells, and/or direct therapeutic activity of those cells.
10.WO/2021/181272BACTERIAL STRAINS AND COMPOSITIONS THEREOF FOR ORAL USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY SYSTEM
WO 16.09.2021
Int.Class A61K 35/744
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
Appl.No PCT/IB2021/051954 Applicant SOFAR S.P.A. Inventor BIFFI, Andrea
The present invention relates to bacterial strains and compositions thereof for use in the treatment of viral infections of the respiratory tract, preferably from coronavirus, such as for example a severe acute respiratory syndrome coronavirus (COVID-19), by stimulating and/or modulating cytokines and/or markers involved in the inflammatory processes of said viral infections of the respiratory tract.